An observational study in Cardiac Sarcoidosis, Sarcoidosis of the Heart and Sarcoidosis With Myocarditis, sponsored by Mayo Clinic. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-17.
Sponsored by Mayo Clinic · Observational
Among 115 studies in Sarcoidosis with a site in United States — 23 open to participants now, 25 under way, 3 of them phase 3. Sarcoidosis · United States.
Among the 115 studies in Sarcoidosis with a site in United States, this one is the 31st largest by planned enrollment of the 46 observational ones that give a count, is one of 4 that started in 2026, is one of 46 observational ones, reaches primary completion later than 13 of the 24 other live ones, and was the 114th registered.
271 studies on the registry are indexed under Sarcoidosis; 51 are open to participants now.
This study's planned enrollment of 115 is below the median of 130 across 109 observational studies indexed under Sarcoidosis.
Browse Sarcoidosis studies →23 of the 115 studies in Sarcoidosis with a site in United States are open now, in 12 countries. Each count lists the studies.
Of the 40 Sarcoidosis studies recruiting now, 30 (75%) set no upper age limit and 1 (3%) stop at 75 or younger; 6 take children under 18; 11 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →115 studies; the count open now beside each. This study's row is marked.
First in 1978; this study’s year is marked. 4 started in 2026.
Median enrollment 16 across the 69 interventional studies, 200 across the 46 observational. Of the 72 that completed or were terminated, 30 (42%) have results posted.
16 of 115 have an industry lead sponsor. The 10 most frequent:
Mayo Clinic is the lead sponsor of 3,269 studies on the registry; 672 are open to participants now.
Of its 452 completed or terminated interventional studies of FDA-regulated products, 321 (71%) have results posted.
Mayo Clinic has 3 studies filed under Sarcoidosis — fewer than ten, so there is no comparison to draw.
7 of the studies in Sarcoidosis with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03593759Phase 3Ottawa Heart Institute Research CorporationCardiac Sarcoidosis Randomized Trial | 2026-12 |
| NCT03621553University of Texas Southwestern Medical CenterVitamin D Homeostasis in Sarcoidosis | 2026-12 |
| NCT07159074Duke UniversityRepurposing Tilmanocept for Cardiac Sarcoidosis | 2026-12-01 |
| NCT05171478Johns Hopkins UniversityFull-Field Optical Coherence Tomography (FFOCT) for Evaluation of Bronchoscopic Small Biopsy Specimens | 2026-12-08 |
| NCT06510894University of PennsylvaniaDiagnostic Utility of SGLT1/2 Inhibition to Facilitate Myocardial Glucose Suppression | 2026-12-31 |
Among the 115 studies in Sarcoidosis with a site in United States, from their registry updates:
The purpose of this study is to develop a prospective cohort of patients with and without cardiac sarcoidosis as well as active and inactive disease to develop a prospective biobank from which exosome analysis of peripheral blood will derive unique biomarkers of disease activity in cardiac sarcoidosis.
Patients referred to the Cardiac Sarcoid Clinic with a clinical suspicion or a previously confirmed diagnosis of cardiac sarcoidosis.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients with a clinical suspicion or a previously confirmed diagnosis of cardiac sarcoidosis.
Other: Exosome Analysis
Blood Samples will undergo exosome profiling using mass spectrometry and/or other discovery-based approaches
Number of successful biomarker validations
Biomarker validation will be defined as ability to discriminate active from inactive or quiescent disease as assessed by FDG-PET
Time frame: Baseline
Plan to share: No
No publications or documents are linked to this record.
Started Jul 2026 (actual). Primary completion is estimated for Jul 2028, 24 months after the start.
Of 59 non-industry observational studies under Sarcoidosis, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 111. This study's planned 24 months is below that.
Counting every sponsor, half of 59 studies reached it within 49 months; a quarter within 20 and three quarters within 111.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.